Alzheimer's disease in the long-term care setting - Management of behavioral disturbances with cholinesterase inhibitors

Annals of Long-Term Care

Volumn 12, Issue 7, 2004, Pages 18-24

  Osterweil, Dan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Spec Ambulatory Assessment Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TACRINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGGRESSION; AKATHISIA; ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; APATHY; BEHAVIOR DISORDER; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COST; DEPRESSION; EDUCATION PROGRAM; EXERCISE; EXTRAPYRAMIDAL SYMPTOM; GAME; HEALTH CARE QUALITY; HUMAN; LIVER TOXICITY; LONG TERM CARE; MASSAGE; MUSIC; NEUROLEPTIC MALIGNANT SYNDROME; NURSING HOME; ORTHOSTATIC HYPOTENSION; PHOTOTHERAPY; PSYCHOSIS; RECREATION; REST; REVIEW; SENSORY STIMULATION; SOCIAL BEHAVIOR; TARDIVE DYSKINESIA; TOUCH;

EID: 3242690681     PISSN: 15247929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Rovner BW, Kafonek S, Filipp L, et al. Prevalence of mental illness in a community nursing home. Am J Psychiatry 1986;143(11):1446-1449.
2. Tariot PN, Padgorski CA, Blazina L, et al. Mental disorders in the nursing home: Another perspective. Am J Psychiatry 1993;150(7):1063-1069.
3. Burns BJ, Wagner HR, Taube JE, et al. Mental health service use by the elderly in nursing homes. Am J Public Health 1993;83(3):331-337.
4. Margallo-Lona M, Swann A, O'Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001;16(1):39-44.
5. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: A natural history study. J Am Geriatr Soc 1996;44(9):1078-1081.
6. Mobily PR, Maas ML, Buckwalter KC, et al. Staff stress on an Alzheimer's unit. J Psychosoc Nurs Ment Healt Serv 1992;30(9):25-31.
7. Kleinman L, Schmier J, Rothman M, et al. Time and costs of managing specific disruptive behaviors in long-term care fertilities: A descriptive study. Consult Pharm 2002;17(6):497-507.
8. Beeri MS, Werner P, Davidson M, et al. The cost of behavioral and psychological symptoms of dementia (BPSD) in community-dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 2002;17(5):403-408.
9. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001;9:361-381.
10. Cohen-Mansfield J, Werner P. Management of verbally disruptive behaviors in nursing home residents. J Gerontol A Biol Sci Med Sci 1997;52(6):M369-377.
11. Rogers JC, Holm MB, Burgio LD, et al. Improving morning care routines of nursing home residents with dementia. J Am Geriatr Soc 1999;47(9):1049-1057.
12. Namazi KH, Gwinnup PB, Zadorozny CA. A low intensity exercisemovement program for patients with Alzheimer's disease: the TEMP-AD protocol. J Aging Phys Act 1994;2:80-92.
13. Holmberg SK. Evaluation of a clinical intervention for wanderers on a geriatric nursing unit. Arch Psychiatry Nurs 1997;11(1):21-28.
14. Aronstein Z, Olsen R, Schulman E. The nursing assistants use of recreational interventions for behavioral management of residents with Alzheimer's disease. Am J Alzheimer's Dis. 1996;May/June:26-31.
15. Sultzer DL, Cummings JL. Alzheimer's disease. In: Rakel R, Conn H, eds. Current Therapy: Latest Approved Methods of Treatment for the Practicing Physician. Philadelphia, PA: WB Saunders; 1993:838-840.
16. Ray WA, Taylor JA, Meador KG, et al. Reducing antipsychotic drug use in nursing homes. A controlled trial of provider education. Arch Intern Med 1993;153(6):713-721.
17. Opie J, Doyle C, O'Connor DW. Challenging behaviours in nursing home residents with dementia: a randomized controlled trial of multidisciplinary interventions. Int J Geriatr Psychiatry 2002;17(1):6-13.
18. Raskind MA, Risse SC, Lampe TH. Dementia and antipsychotic drugs. J Clin Psychiatry. 1987;48 Suppl:16-18.
19. Desai A, Grossberg, GT. Recognition and management of behavioral disturbances in dementia. Prim Care Companion J Clin Psychiatry 2001;3:93-109.
20. Proctor R, Burns A, Powell HS, et al. Behavioural management in nursing and residential homes: a randomised controlled trial. Lancet 1999;354(9172): 26-29.
21. Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic anti-depressants in depression: systematic review. BMJ 2002;325(7371):991.
22. Cummings JL. Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 2000;157(1):4-15.
23. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. J Geriatr Psychiatry Neurol 1996;9(1):1-6.
24. Trinh NH, Hoblyn J, Mohanty, S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairmemt in Alzheimer disease: a meta-analysis. JAMA 2003;289(2):210-216.
25. Kaufer DI, Cummings JL, Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: Relationship to dementia severily. J Neuropsychiatry Clin Neurosci 1998:10(1): 55-63.
26. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54(12):2269-2276.
27. Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002;14(4):389-404.
28. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57(4):613-620.
29. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
30. Gauthier S, Feldman H, Hecker J, et al. Functional, cognitive and behavioral benefits of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin 2002;18(6):347-354.
31. Mego MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46(1):130-135.
32. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 1998;20:838-850.
33. Rabinowicz A, Koumaros B, Cummings J, et al. Effects of rivastigmine treatment on the psychiatric and behavioral disturbances of nursing home residents moderate to severe Alzheimer's disease (final results). Paper presented at: 11th Annual Congress of the International Psychiatric Association; Aug 18-22, 2003; Chicago, Ill.
34. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-1599.
35. Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. Am J Geriatr Psychiatry 2000;8(2):134-140.
36. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003;51(6):737-744.